Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 1
2003 1
2004 3
2005 4
2006 4
2007 4
2010 5
2011 7
2012 4
2013 1
2014 7
2015 6
2016 6
2017 9
2018 6
2019 6
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

72 results
Results by year
Filters applied: . Clear all
Page 1
DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
Töpfer K, Cartellieri M, Michen S, Wiedemuth R, Müller N, Lindemann D, Bachmann M, Füssel M, Schackert G, Temme A. Töpfer K, et al. Among authors: temme a. J Immunol. 2015 Apr 1;194(7):3201-12. doi: 10.4049/jimmunol.1400330. Epub 2015 Mar 4. J Immunol. 2015. PMID: 25740942 Free article.
Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N, Michen S, Tietze S, Töpfer K, Schulte A, Lamszus K, Schmitz M, Schackert G, Pastan I, Temme A. Müller N, et al. Among authors: temme a. J Immunother. 2015 Jun;38(5):197-210. doi: 10.1097/CJI.0000000000000082. J Immunother. 2015. PMID: 25962108 Free PMC article.
"UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.
Mitwasi N, Feldmann A, Arndt C, Koristka S, Berndt N, Jureczek J, Loureiro LR, Bergmann R, Máthé D, Hegedüs N, Kovács T, Zhang C, Oberoi P, Jäger E, Seliger B, Rössig C, Temme A, Eitler J, Tonn T, Schmitz M, Hassel JC, Jäger D, Wels WS, Bachmann M. Mitwasi N, et al. Among authors: temme a. Sci Rep. 2020 Feb 7;10(1):2141. doi: 10.1038/s41598-020-59082-4. Sci Rep. 2020. PMID: 32034289 Free PMC article.
Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin.
Biedermann J, Preussler M, Conde M, Peitzsch M, Richter S, Wiedemuth R, Abou-El-Ardat K, Krüger A, Meinhardt M, Schackert G, Leenders WP, Herold-Mende C, Niclou SP, Bjerkvig R, Eisenhofer G, Temme A, Seifert M, Kunz-Schughart LA, Schröck E, Klink B. Biedermann J, et al. Among authors: temme a. Cancers (Basel). 2019 Dec 16;11(12):2028. doi: 10.3390/cancers11122028. Cancers (Basel). 2019. PMID: 31888244 Free PMC article.
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.
Tunger A, Kießler M, Wehner R, Temme A, Meier F, Bachmann M, Schmitz M. Tunger A, et al. Among authors: temme a. Biomedicines. 2018 Mar 1;6(1):26. doi: 10.3390/biomedicines6010026. Biomedicines. 2018. PMID: 29494517 Free PMC article. Review.
Toxicological investigations of "naked" and polymer-entrapped AOT-based gold nanotriangles.
Liebig F, Moreno S, Thünemann AF, Temme A, Appelhans D, Koetz J. Liebig F, et al. Among authors: temme a. Colloids Surf B Biointerfaces. 2018 Jul 1;167:560-567. doi: 10.1016/j.colsurfb.2018.04.059. Epub 2018 Apr 30. Colloids Surf B Biointerfaces. 2018. PMID: 29734066
RhoGDIβ affects HeLa cell spindle orientation following UVC irradiation.
Doi N, Kunimatsu Y, Fujiura K, Togari H, Minagi K, Nakaoji K, Hamada K, Temme A, Tatsuka M. Doi N, et al. Among authors: temme a. J Cell Physiol. 2019 Jan 16. doi: 10.1002/jcp.28154. Online ahead of print. J Cell Physiol. 2019. PMID: 30652309
AMPA Receptor Antagonist CFM-2 Decreases Survivin Expression in Cancer Cells.
Ruiz DS, Luksch H, Sifringer M, Temme A, Staufner C, Rzeski W, Marzahn J, Grabarska A, Ikonomidou C, Stepulak A. Ruiz DS, et al. Among authors: temme a. Anticancer Agents Med Chem. 2018;18(4):591-596. doi: 10.2174/1871520618666180228123406. Anticancer Agents Med Chem. 2018. PMID: 29493464
Bivalent Peptide- and Chelator-Containing Bioconjugates as Toolbox Components for Personalized Nanomedicine.
Daeg J, Xu X, Zhao L, Boye S, Janke A, Temme A, Zhao J, Lederer A, Voit B, Shi X, Appelhans D. Daeg J, et al. Among authors: temme a. Biomacromolecules. 2020 Jan 13;21(1):199-213. doi: 10.1021/acs.biomac.9b01127. Epub 2019 Nov 4. Biomacromolecules. 2020. PMID: 31619036
Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S, Temme A. Michen S, et al. Among authors: temme a. Crit Rev Immunol. 2016;36(4):329-347. doi: 10.1615/CritRevImmunol.2017019376. Crit Rev Immunol. 2016. PMID: 28322137 Review.
72 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback